<DOC>
	<DOCNO>NCT00415597</DOCNO>
	<brief_summary>Open-Label , Safety Study evaluate long-term safety Kadian NT ( ALO-01 ) administer 12 month .</brief_summary>
	<brief_title>Study Embeda ( Kadian NT , ALO-01 ) Subjects With Chronic Moderate Severe Nonmalignant Pain</brief_title>
	<detailed_description />
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Subject 1870 year age Subject agree refrain take opioid medication study medication study period . History chronic moderate severe pain cause nonmalignant condition least 3 month prior baseline Subject documented history allergic reaction clinically significant intolerance morphine opioids , treatment morphine contraindicate . Subject pregnant breastfeeding . Subject receive chemotherapy , active malignancy type diagnose cancer within past three year ( exclude squamous basal cell carcinoma skin ) . Subject documented history drug abuse/dependence/misuse narcotic analgesic abuse/dependence/misuse within five year prior Baseline Visit . Subject Body Mass Index ( BMI ) &gt; 45kg/m2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>chronic pain</keyword>
	<keyword>joint pain</keyword>
	<keyword>back pain</keyword>
	<keyword>diabetic peripheral neuropathy</keyword>
	<keyword>post herpetic neuralgia</keyword>
	<keyword>ALO-01</keyword>
	<keyword>Embeda</keyword>
	<keyword>Chronic Non-Malignant Pain</keyword>
</DOC>